CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 5.71: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.90%Above 5Y avg (2.97%)
Annual Rate
CNY 0.40Paid annual
Payout Ratio
120.0%High
Payback Period
25.7 yr
Last Ex-Dividend
Jun 16, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.67BCNY545.51M · vs all stocks (USD)
Trailing P/E
20.76xvs Biotechnology peers
Revenue (TTM)
1.06BCNY157.71M · vs all stocks (USD)
Profit Margin
16.30%vs Biotechnology peers
Beta
0.2950xvs all stocks
52-Week Change
-33.14%vs all stocks
Market Capitalization
3.67BCNY545.51M · vs all stocks (USD)
Enterprise Value
3.01BCNY448.04M · vs all stocks (USD)
Trailing P/E
20.76xvs Biotechnology peers
Forward P/E
12.66xvs Biotechnology peers
Price to Sales (TTM)
3.39xvs Biotechnology peers
Price to Book (MRQ)
1.34xvs Biotechnology peers
Enterprise to Revenue
2.84xvs Biotechnology peers
Enterprise to EBITDA
10.97xvs Biotechnology peers
Gross Margin
54.89%vs Biotechnology peers
Profit Margin
16.30%vs Biotechnology peers
Operating Margin
15.59%vs Biotechnology peers
Return on Assets (TTM)
3.06%vs Biotechnology peers
Return on Equity (TTM)
6.15%vs Biotechnology peers
Revenue (TTM)
1.06BCNY157.71M · vs all stocks (USD)
Revenue per Share (TTM)
3.08CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-10.50%vs Biotechnology peers
Gross Profit (TTM)
622.98MCNY92.64M · vs all stocks (USD)
EBITDA (TTM)
196.27MCNY29.19M · vs all stocks (USD)
Net Income (TTM)
172.82MCNY25.70M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-23.00%vs Biotechnology peers
Operating Cash Flow (TTM)
272.92MCNY40.59M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
55.79MCNY8.30M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.4000CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
3.90%vs all stocks
5-Year Average Dividend Yield
2.97%vs all stocks
Payout Ratio
120.00%vs Biotechnology peers
Minority Interest (Equity)
130.92MCNYFY2025 · Dec 31, 2025Revenue
1.09BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
437.35MCNYFY2025 · Dec 31, 2025Gross Profit
652.53MCNYFY2025 · Dec 31, 2025Operating Income
190.14MCNY28.28M · vs all stocks (USD)
Pre-tax Income
207.34MCNYFY2025 · Dec 31, 2025Income Tax Expense
22.34MCNYFY2025 · Dec 31, 2025Net Income
184.99MCNYFY2025 · Dec 31, 2025EBIT
207.40MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
317.96MCNYFY2025 · Dec 31, 2025Research & Development
99.65MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
202.97MCNYFY2025 · Dec 31, 2025Other Operating Expenses
17.07MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.17MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
59.75KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
342.58MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
342.58MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
184.99MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
255.16MCNYFY2025 · Dec 31, 2025Free Cash Flow
180.23MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
132.74MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
184.99MCNYFY2025 · Dec 31, 2025Other Non-cash Items
943.52KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
47.17MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
22.05MCNYFY2025 · Dec 31, 2025Capital Expenditures
-74.93MCNYFY2025 · Dec 31, 2025Net Acquisitions
-9.18MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.90BCNYFY2025 · Dec 31, 2025Sale of Investments
2.77BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-217.56MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-205.15MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.39MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-206.54MCNYFY2025 · Dec 31, 2025Shares Outstanding
346.06MSharesUpdated Aug 21, 2026Float Shares
206.55MSharesUpdated Aug 21, 2026% Held by Insiders
45.70%vs all stocks
% Held by Institutions
2.42%vs all stocks
Total Cash (MRQ)
754.34MCNY112.18M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.21CNYUpdated Aug 21, 2026Total Debt (MRQ)
27.24MCNY4.05M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0098xvs Biotechnology peers
Current Ratio (MRQ)
3.82xvs Biotechnology peers
Book Value per Share (MRQ)
7.74CNYUpdated Aug 21, 2026Total Assets
3.24BCNY481.35M · vs all stocks (USD)
Total Current Assets
1.37BCNYFY2025 · Dec 31, 2025Total Liabilities
500.00MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.87BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
74.86MCNYFY2025 · Dec 31, 2025Total Current Liabilities
425.14MCNYFY2025 · Dec 31, 2025Cash
132.60MCNYFY2025 · Dec 31, 2025Cash Equivalents
4.71MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
137.31MCNYFY2025 · Dec 31, 2025Other Short-term Investments
635.85MCNYFY2025 · Dec 31, 2025Accounts Receivable
350.67MCNYFY2025 · Dec 31, 2025Inventory
219.73MCNYFY2025 · Dec 31, 2025Accounts Payable
135.81MCNYFY2025 · Dec 31, 2025Short-term Debt
6.95MCNYFY2025 · Dec 31, 2025Other Current Liabilities
672.34KCNYFY2025 · Dec 31, 2025Long-term Debt
20.29MCNYFY2025 · Dec 31, 2025Common Stock (Book)
346.06MCNYFY2025 · Dec 31, 2025Retained Earnings
942.67MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.74BCNY407.00M · vs all stocks (USD)
Treasury Stock
60.34MCNYFY2025 · Dec 31, 202552-Week Low
9.56CNYUpdated Aug 21, 202652-Week High
15.79CNYUpdated Aug 21, 202652-Week Change
-33.14%vs all stocks
Beta
0.2950xvs all stocks
50-Day MA
10.30CNYUpdated Aug 21, 2026200-Day MA
12.23CNYUpdated Aug 21, 2026Avg 10-Day Volume
3.84MSharesUpdated Aug 21, 2026Avg 30-Day Volume
3.48MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.5000CNYUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
How is this stock valued?
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.71: safe zoneNotable
Altman Z-Score: 5.71
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Sailun Biotech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NeuroPace Inc.
Tier 1ProductionApproval-Gated PipelineRule
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
TaiMed Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Relmada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Well Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guangdong Lifestrong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Jiangsu Tianmu Lake Tourism Co. Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedPrice Below Mean With Profitability And Equity
Shanghai Flyco Electrical Co., Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedPrice Below Mean With Profitability And Equity
Cabio Biotech Wuhan Co., Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedPrice Below Mean With Profitability And Equity